Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the … read more 17th Dec 2025 Shanza Riaz
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody tar … read more 16th Jan 2025 Marina Alberto
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjuga … read more 16th Jan 2025 Marina Alberto
